These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 11256849)

  • 1. Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin.
    Olsson AG
    Am J Cardiol; 2001 Mar; 87(5A):33B-36B. PubMed ID: 11256849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new statin: a new standard.
    Olsson AG
    Clin Cardiol; 2001 Aug; 24(8 Suppl):III18-23. PubMed ID: 11501599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
    Olsson AG; McTaggart F; Raza A
    Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
    Olsson AG; Pears J; McKellar J; Mizan J; Raza A
    Am J Cardiol; 2001 Sep; 88(5):504-8. PubMed ID: 11524058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.
    Saito Y; Goto Y; Dane A; Strutt K; Raza A
    J Atheroscler Thromb; 2003; 10(6):329-36. PubMed ID: 15037821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel statins: pharmacological and clinical results.
    Bolego C; Poli A; Cignarella A; Catapano AL; Paoletti R
    Cardiovasc Drugs Ther; 2002 May; 16(3):251-7. PubMed ID: 12374904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the pharmacology of statins: characteristics of rosuvastatin.
    Chapman MJ; McTaggart F
    Atheroscler Suppl; 2002 Apr; 2(4):33-6; discussion 36-7. PubMed ID: 11976075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
    Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
    Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW;
    Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of efficacy of rosuvastatin 5 mg.
    Teramoto T; Watkins C
    Int J Clin Pract; 2005 Jan; 59(1):92-101. PubMed ID: 15707472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New dimension of statin action on ApoB atherogenicity.
    Chapman MJ; Caslake M; Packard C; McTaggart F
    Clin Cardiol; 2003 Jan; 26(1 Suppl 1):I7-10. PubMed ID: 12539816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.
    Mackie BD; Satija S; Nell C; Miller J; Sperling LS
    Am J Cardiol; 2007 Jan; 99(2):291. PubMed ID: 17223437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches to lipid lowering: what is on the horizon?
    Brown WV
    Am J Cardiol; 2001 Mar; 87(5A):23B-27B. PubMed ID: 11256846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.